Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
AAB-003 PF-05236812 Alzheimer's Disease (Phase 1) Janssen, Pfizer Amyloid-Related Immunotherapy (passive)
Aducanumab BIIB037 Alzheimer's Disease (Phase 3) Biogen Amyloid-Related Immunotherapy (passive)
BAN2401 Alzheimer's Disease (Phase 2) Biogen, Eisai Co., Ltd. Amyloid-Related Immunotherapy (passive)
BIIB092 BMS-986168, IPN007 Progressive Supranuclear Palsy (Phase 1) Biogen, Bristol-Myers Squibb Tau Immunotherapy (passive)
Bapineuzumab AAB-001 Alzheimer's Disease (Discontinued) Janssen, Pfizer Amyloid-Related Immunotherapy (passive)
C2N 8E12 ABBV-8E12 Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) AbbVie, C2N Diagnostics, LLC Tau Immunotherapy (passive)
Crenezumab MABT5102A ,
Alzheimer's Disease (Phase 3) AC Immune SA, Genentech, Hoffmann-La Roche Amyloid-Related Immunotherapy (passive) None
Etanercept Enbrel™ Alzheimer's Disease (Phase 2) Amgen, Inc., Pfizer Inflammation Immunotherapy (passive) Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondilysis
GSK933776 Alzheimer's Disease (Inactive) GlaxoSmithKline (GSK) Amyloid-Related Immunotherapy (passive)
Gammagard® Intravenous Immunoglobulin,
Alzheimer's Disease (Discontinued) Baxter Healthcare Amyloid-Related, Inflammation Immunotherapy (passive) Immunodeficiency conditions
Gamunex Intravenous Immunoglobulin,
Human Albumin Combined With Flebogamma
Alzheimer's Disease (Phase 2/3) Grifols Biologicals Inc. Amyloid-Related, Inflammation Immunotherapy (passive) Immunodeficiency, chronic inflammatory demyelinating neuropathy
Gantenerumab RO4909832,
Alzheimer's Disease (Phase 3) Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Amyloid-Related Immunotherapy (passive)
LY2599666 Alzheimer's Disease (Phase 1) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)
LY3002813 N3pG-Aβ Monoclonal Antibody Alzheimer's Disease (Phase 1) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)
LY3303560 Alzheimer's Disease (Phase 1) Eli Lilly & Co. Unknown Immunotherapy (passive)
MEDI1814 Alzheimer's Disease (Phase 1) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)
Octagam®10% Intravenous Immunoglobulin,
Alzheimer's Disease (Inactive), Mild Cognitive Impairment (Inactive) Octapharma Amyloid-Related, Inflammation Immunotherapy (passive) Immunodeficiency disorders
PRX002 RG7935, NEOD002 Parkinson's Disease (Phase 1) Prothena Corporation plc, Roche alpha-synuclein Immunotherapy (passive)
Ponezumab PF-04360365 Alzheimer's Disease (Discontinued), Cerebral Amyloid Angiopathy (Phase 2) Pfizer Amyloid-Related Immunotherapy (passive) None
RG7345 RO6926496 Alzheimer's Disease (Discontinued) Roche Tau Immunotherapy (passive)
RO 7105705 RG 6100 Alzheimer's Disease (Phase 1) AC Immune SA, Genentech, Hoffmann-La Roche Tau Immunotherapy (passive)
SAR228810 Alzheimer's Disease (Phase 1) Sanofi Amyloid-Related Immunotherapy (passive)
Solanezumab LY2062430 Alzheimer's Disease (Phase 3) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive) None